Aliskiren corrects recurrent hyperreninemia and hyperaldosteronism in autosomal dominant polycystic kidney disease.
A 47-year-old woman with family history of autosomal-dominant polycystic kidney disease (ADPKD), who underwent living-donor kidney transplantation in 2000, presented with recurrent edema, hyperreninemia, and hyperaldosteronism. Since 2002, her antihypertensive therapy comprised ramipril and spironolactone. The post-transplantation kidney function was stable. Based on the clinical picture and reports of renin secretion by renal cysts in ADPKD, we performed a trial of aliskiren therapy (300 mg/day). The patient showed excellent blood pressure control and reduction of edema, with aldosterone levels normalizing within 2 months. This is a novel report of aliskiren therapy for treatment of edema, hyperreninemia, and hyperaldosteronism in ADPKD.
Amico
P
P
Department of Internal Medicine, University of Basel, Division of Nephrology, Kantonsspital, Liestal, Switzerland.
Kalbermatter
S
S
Kiss
D
D
D000577:Amides / Q000627:therapeutic use*; D005260:Female; D005650:Fumarates / Q000627:therapeutic use*; D006801:Humans; D006929:Hyperaldosteronism / Q000188:drug therapy* / Q000209:etiology*; D008875:Middle Aged; D016891:Polycystic Kidney, Autosomal Dominant / Q000097:blood* / Q000150:complications*; D012008:Recurrence; D012074:Remission Induction; D012083:Renin / Q000097:blood*
D000577:Amides; D005650:Fumarates; C446481:aliskiren; D012083:Renin